Immunotherapy for hormone receptor-positive HER2-negative breast cancer

被引：1

作者：

Cardoso, Fatima ^{[1
]}

Hirshfield, Kim M. ^{[2
]}

Kraynyak, Kimberly A. ^{[2
]}

Tryfonidis, Konstantinos ^{[2
]}

Bardia, Aditya ^{[3
]}

机构：

[1] Champalimaud Fdn, Champalimaud Clin Ctr, Breast Unit, Lisbon, Portugal

[2] Merck & Co Inc, Rahway, NJ USA

[3] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Med, Div Hematol Oncol, Los Angeles, CA USA

来源：

NPJ BREAST CANCER | 2024年 / 10卷 / 01期

关键词：

PEMBROLIZUMAB PLUS CHEMOTHERAPY; TUMOR-INFILTRATING LYMPHOCYTES; ADJUVANT ENDOCRINE THERAPY; OPEN-LABEL; HIGH-RISK; NEOADJUVANT CHEMOTHERAPY; LOCALLY RECURRENT; NIVOLUMAB NIVO; TRIAL; PALBOCICLIB;

D O I：

10.1038/s41523-024-00704-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Additional therapies are needed to improve outcomes in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. Research on the potential role of immunotherapy, particularly programmed cell death protein 1/programmed cell death ligand 1 inhibitors, is rapidly expanding in both the early and metastatic settings with some preliminary evidence suggesting benefit when used as part of combination therapy. Several ongoing phase 3 studies should help define their future role in treating these patients.

引用

页数：15

共 92 条

[11] KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. [J].

Cardoso, Fatima ;

Bardia, Aditya ;

Andre, Fabrice ;

Cescon, David W. ;

McArthur, Heather L. ;

Telli, Melinda L. ;

Loi, Sherene ;

Cortes, Javier ;

Schmid, Peter ;

Harbeck, Nadia ;

Denkert, Carsten ;

Jackisch, Christian ;

Jia, Liyi ;

Hirshfield, Kim M. ;

Karantza, Vassiliki .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[12] Cellular immunity in breast cancer patients completing taxane treatment [J].

Carson, WE ;

Shapiro, CL ;

Crespin, TR ;

Thornton, LM ;

Andersen, BL .

CLINICAL CANCER RESEARCH, 2004, 10 (10) :3401-3409

[13] Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors [J].

Centanni, Maddalena ;

Moes, Dirk Jan A. R. ;

Troconiz, Inaki F. ;

Ciccolini, Joseph ;

van Hasselt, J. G. Coen .

CLINICAL PHARMACOKINETICS, 2019, 58 (07) :835-857

[14] Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].

Cortazar, Patricia ;

Zhang, Lijun ;

Untch, Michael ;

Mehta, Keyur ;

Costantino, Joseph P. ;

Wolmark, Norman ;

Bonnefoi, Herve ;

Cameron, David ;

Gianni, Luca ;

Valagussa, Pinuccia ;

Swain, Sandra M. ;

Prowell, Tatiana ;

Loibl, Sibylle ;

Wickerham, D. Lawrence ;

Bogaerts, Jan ;

Baselga, Jose ;

Perou, Charles ;

Blumenthal, Gideon ;

Blohmer, Jens ;

Mamounas, Eleftherios P. ;

Bergh, Jonas ;

Semiglazov, Vladimir ;

Justice, Robert ;

Eidtmann, Holger ;

Paik, Soonmyung ;

Piccart, Martine ;

Sridhara, Rajeshwari ;

Fasching, Peter A. ;

Slaets, Leen ;

Tang, Shenghui ;

Gerber, Bernd ;

Geyer, Charles E., Jr. ;

Pazdur, Richard ;

Ditsch, Nina ;

Rastogi, Priya ;

Eiermann, Wolfgang ;

von Minckwitz, Gunter .

LANCET, 2014, 384 (9938) :164-172

[15] Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer [J].

Cortes, J. ;

Rugo, H. S. ;

Cescon, D. W. ;

Im, S-A ;

Yusof, M. M. ;

Gallardo, C. ;

Lipatov, O. ;

Barrios, C. H. ;

Perez-Garcia, J. ;

Iwata, H. ;

Masuda, N. ;

Otero, M. Torregroza ;

Gokmen, E. ;

Loi, S. ;

Guo, Z. ;

Zhou, X. ;

Karantza, V ;

Pan, W. ;

Schmid, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (03) :217-226

[16]

Cortes J, 2020, LANCET, V396, P1817, DOI 10.1016/S0140-6736(20)32531-9

[17] A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2-primary breast cancer: CheckMate 7FL [J].

Curigliano, G. ;

McArthur, H. ;

Harbeck, N. ;

Pusztai, L. ;

Delaloge, S. ;

Letrent, K. ;

Chen, T. ;

Li, B. ;

Tatsuoka, K. ;

Zardavas, D. ;

Loi, S. .

ANNALS OF ONCOLOGY, 2020, 31 :S60-S61

[18] Clinicopathological and prognostic significance of programmed cell death ligand 1 expression in patients diagnosed with breast cancer: meta-analysis [J].

Davey, M. G. ;

Ryan, E. J. ;

Davey, M. S. ;

Lowery, A. J. ;

Miller, N. ;

Kerin, M. J. .

BRITISH JOURNAL OF SURGERY, 2021, 108 (06) :622-631

[19] First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial [J].

De Caluwe, Alex ;

Romano, Emanuela ;

Poortmans, Philip ;

Gombos, Andrea ;

Agostinetto, Elisa ;

Marta, Guilherme Nader ;

Denis, Zoe ;

Drisis, Stylianos ;

Vandekerkhove, Christophe ;

Desmet, Antoine ;

Philippson, Catherine ;

Craciun, Ligia ;

Veys, Isabelle ;

Larsimont, Denis ;

Paesmans, Marianne ;

Van Gestel, Dirk ;

Salgado, Roberto ;

Sotiriou, Christos ;

Piccart-Gebhart, Martine ;

Ignatiadis, Michail ;

Buisseret, Laurence .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (12)

[20] Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy [J].

Denkert, Carsten ;

von Minckwitz, Gunter ;

Darb-Esfahani, Silvia ;

Lederer, Bianca ;

Heppner, Barbara I. ;

Weber, Karsten E. ;

Budczies, Jan ;

Huober, Jens ;

Klauschen, Frederick ;

Furlanetto, Jenny ;

Schmitt, Wolfgang D. ;

Blohmer, Jens-Uwe ;

Karn, Thomas ;

Pfitzner, Berit M. ;

Kuemmel, Sherko ;

Engels, Knut ;

Schneeweiss, Andreas ;

Hartmann, Arndt ;

Noske, Aurelia ;

Fasching, Peter A. ;

Jackisch, Christian ;

van Mackelenbergh, Marion ;

Sinn, Peter ;

Schem, Christian ;

Hanusch, Claus ;

Untch, Michael ;

Loibl, Sibylle .

LANCET ONCOLOGY, 2018, 19 (01) :40-50

← 1 2 3 4 5 6 7 8 9 10 →